- About the Center
- Research Programs
- Addiction Genetics and Pharmacogenetics Division
- Addiction Treatment and Medication Development Division
- Brain-Behavioral Vulnerabilities Laboratory
- HIV/AIDS Prevention Research Division
- Clinical Trials Network
- Novel Interventions in Criminal Justice Populations Division
- Continuing Care and Assessment Division
- Integrated Care for Primary Care
- Clinical Trial Participation
- Treatment Options
- Affiliated Divisions
- Center Faculty
- Post Doctoral Fellowships
- Recorded Seminars
- Public Education and Policy Work
- Contact Us
- Support Our Work
Welcome to the CSA
The primary mission of the CSA is to advance knowledge on the nature of addiction and the best ways to treat the disorder. Our research is translational in two directions. We apply knowledge from the preclinical laboratory to clinical trials in a university setting. We also translate knowledge learned from clinical trials to the practitioners in the community. Thus, the medications and behavioral treatments discovered or refined in our research can have an impact on the care received by patients all over the world.
Another key component of our Center’s mission is the development and maintenance of educational programs on the causes of addiction and the best methods to assess and treat the disorder. The design and content of our educational programs strongly reflect the field’s significant research findings, much of which come from studies conducted at the Center. Included in these programs is the University’s teaching on addiction, a key component of the Penn medical student’
s curriculum. We also train psychiatric residents and residents in medicine and primary care. We have an ACGME-approved fellowship training program for clinicians desiring board certification in Addiction Psychiatry and an NIH-funded addiction research training program for PhDs and MDs.
Research findings that influenced the design of our educational programs have also provided the framework for our patient care practices. The methods we use to diagnose the presence and severity of addictive disorders and the interventions for treating them are evidenced-based protocols. Individuals seeking treatment for substance-related addictions may receive care through one of the following:
1. Referral to one of the Center’s clinical trials to learn the details of the study and to determine eligibility for enrollment,
2. Referral to the fee-based, private-practice treatment program located at the O’Brien Center, or
3. Assistance in arranging a self-referral to one of the local community-based treatment programs.
CSA In the News
Kyle Kampman, MD, Kevin Lynch, PhD, James McKay, PhD, Daniel Langleben, MD, George Woody, MD, and David Oslin, MD will investigate treatment strategies for opioid use disorder as part of a new NIH initiative - Helping to End Addiction Long-term (HEAL).
Henry R. Kranzler, MD (Professor of Psychiatry and Director of the Center for Studies of Addiction) discusses his latest genetic research, which indicates that heavy drinking is not a sufficient cause of Alcohol Use Disorder (AUD) despite it being a risk factor.
Anna Rose Childress, PhD (Research Professor of Psychology in Psychiatry) was interviewed about the spike in overdoses due to an unbeknownst combination of crack cocaine and the synthetic opioid fentanyl.
Henry R. Kranzler, MD (Professor of Psychiatry and Director of the Center for Studies of Addiction) was interviewed about genetics and possible risk factors with opiate abuse.
Henry R. Kranzler, MD was featured by Penn Medicine and his 2017 Precision Medicine Accelerator Fund project examining the genetics of orthopaedic surgery patients and opioids.